Going Beyond the Limits of Legacy Pharmacovigilance with Real-World Data
The revolution in drug safety data is underway. The advent of RWD, together with technologies to aggregate, standardize, and analyze it, have turned Pharmacovigilance (PV) specialists into evidence generation leaders.
See how TriNetX is supporting the forefront of pharmacovigilance with an unmatched, panoramic view of real-word, global patient data. Starting from our GVP-IX compliant platform for automated signal detection and management, we’ll follow a path from simple adverse event disproportionality to the evidence for drug attributability. Along the way, we’ll show you the tools and data that speed the time to resolution while enriching the possibilities for analysis, thus unlocking the full power of drug safety data from both internal and disparate data sources.
Chief Product Officer
Advera Health Analytics, Inc.
Jeffrey Brown, PhD
Chief Scientific Officer
Arnold Chan, ScD
Vice President of RWE
Solomon Iyasu, MD, MPH, FISPE
Independent Consultant: Epidemiology, Drug and Biologics Safety & Regulatory Use of RWD/RWE